Aprea Therapeutics, Inc. (APRE) Stock Profile — Insider Trades & Financials

Net Income-$2.5M

EPS$-1.65

Market Cap$8.0M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Oren Gilad

CEO & Executive Director

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.

Founded: 2006
Employees: 8
Headquarters: Doylestown, Pennsylvania, United States

⚡

Core Efficiency

ROE?

-19.74%

ROA?

-15.41%

📊

Profitability Ratios

Current Ratio?

5.63

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Sep 6, 2026 (in 150 days)

Annual Report (10-K) — Based on filing pattern

Sep 6, 2026

Predicted10-K

Mar 16, 2026

10-KQ4 20250d after period end

Mar 16, 2026

10-KFY 202575d after period end

Nov 12, 2025

10-QQ3 20251d after period end

Aug 12, 2025

10-QQ2 20251d after period end

May 14, 2025

10-QQ1 20251d after period end

Mar 25, 2025

10-KQ4 20240d after period end

Mar 25, 2025

10-KFY 202584d after period end

Nov 7, 2024

10-QQ3 20240d after period end

Loading company sections...

Aprea Therapeutics, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness